Week -3: baseline
Week 0: 20 μg wIFN-α or placebo
Week 3: 20 μg wIFN-α or placebo
Week 7: 100 μg wIFN-α or placebo
Week 11: 100 μg wIFN-α or placebo
Week 15: 100 μg wIFN-α or placebo
Week 17: follow-up
Week 19: follow-up
Week 23: follow-up
Week 25: follow-up

Placebo wIFN-α on-treatment samples (20 μg and 100 μg doses)
All placebo samples wIFN-α pre- and post-treatment samples